Takeda Patent-Cliff Exposure & CMS Drug Spending Portfolio
Takeda (Cambridge, MA): 59 reconciled FDA prescription therapies (6.3% 2025 to 2030 cliff risk), $6.15B 2024 CMS Part D & Medicaid spend, and 80 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Cambridge, MA |
| Reconciled FDA Portfolio Therapies | 59 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 6.3% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $6.15B |
| 2024 Medicare Part D Spend | $2.95B |
| 2024 Medicaid Spend | $3.21B |
| California HCAI SB 17 Filings | 80 WAC filings (max 24.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.